Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.
2022 Startups to Watch
stats here
Related Posts on Startland News
CB Insights calls KCRise most active VC in Kansas; Fund credits work of small team, innovative portfolio startups
Kansans don’t fear hard work, said Darcy Howe. An investment in such a mindset has come with big returns for the KCRise Fund, newly proclaimed the most active venture capital fund in the Sunflower State, according to CB Insights. “Perhaps overused but Margaret Mead’s quote, ‘Never doubt that a small group of thoughtful, committed citizens…
Overland Park-based CAPS education network launching cross-cultural program in India
The Center for Advanced Professional Studies’ (CAPS) first international affiliate program in India has the potential to break down geographic barriers to provide students with exposure to real workplace experiences on a global stage, said Corey Mohn. “I think [the American School of Bombay] is really the perfect partner to get started with,” said Mohn,…
New $750K investment round for Lula comes with partner in apartment management
Closing a $750,000 seed round is even more impactful with a strategic partner like Worcester Investments, said Lula founder Bo Lais. “We did have three other private investors, that were minority investors with two of them local, but it’s [become] more than just investment with [with Worcester],” said Lais, CEO of the Overland Park-based home…
Chronic Cow uses big data to attack pain: ‘I can still live a good life,’ founder with MS says
Half of all Americans have a chronic illness, said former TeraCrunch co-founder Dr. Kevin Payne. That somber reality, paired with uninvolved physicians, makes quality of life difficult for patients and the focus of Payne’s new venture, Chronic Cow, he said. “From a medical perspective, all I can do as a patient is what my physicians…